Literature DB >> 12074366

Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration.

Beth M McMahon1, Dennis Mays, James Lipsky, Jennifer A Stewart, Abdul Fauq, Elliott Richelson.   

Abstract

Peptide nucleic acids (PNAs) are DNA analogs that hybridize to complementary nucleic sequences with high affinity and stability. In our previous work, we showed that a PNA complementary to a 12-base pair (bp) sequence of the coding region of the rat neurotensin receptor (rNTR1) mRNA is effective in significantly blocking a rat's central responses to neurotensin (NT), even when the PNA is injected intraperitoneally (i.p.). Using a novel gel shift detection assay to detect PNA, we have now used this same PNA sequence to derive its pharmacokinetic variables and its tissue distribution in the rat. The PNA has a distribution half-life of 3 +/- 3 minutes and an elimination half-life of 17 +/- 3 minutes. The total plasma clearance and volume of distribution of this PNA were 3.4 +/- 0.9 ml/min x kg and 60 +/- 30 ml/kg. Two hours after dosing, the PNA was found at detectable but low levels in all organs examined-in order of decreasing concentration: kidney, liver, heart, brain, and spleen. Approximately 90% of the PNA dose was recovered as unchanged parent compound in the urine 24 hours after administration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12074366     DOI: 10.1089/108729002760070803

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  24 in total

Review 1.  PNA Technology.

Authors:  Peter E Nielsen
Journal:  Mol Biotechnol       Date:  2004-03       Impact factor: 2.695

2.  Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissue.

Authors:  Edward V Wancewicz; Martin A Maier; Andrew M Siwkowski; Klaus Albertshofer; Theodore M Winger; Andres Berdeja; Hans Gaus; Timothy A Vickers; C Frank Bennett; Brett P Monia; Richard H Griffey; Christopher J Nulf; Jiaxin Hu; David R Corey; Eric E Swayze; Garth A Kinberger
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

Review 3.  Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.

Authors:  Tae Jin Lee; Xiaoyi Yuan; Keith Kerr; Ji Young Yoo; Dong H Kim; Balveen Kaur; Holger K Eltzschig
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 4.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

5.  Targeted gene modification of hematopoietic progenitor cells in mice following systemic administration of a PNA-peptide conjugate.

Authors:  Faye A Rogers; Sharon S Lin; Denise C Hegan; Diane S Krause; Peter M Glazer
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

Review 6.  Canonical and non-canonical barriers facing antimiR cancer therapeutics.

Authors:  Christopher J Cheng; W Mark Saltzman; Frank J Slack
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 7.  Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases.

Authors:  Kathleen M Schoch; Timothy M Miller
Journal:  Neuron       Date:  2017-06-21       Impact factor: 17.173

8.  Methods for assessing DNA hybridization of peptide nucleic acid-titanium dioxide nanoconjugates.

Authors:  Eric M B Brown; Tatjana Paunesku; AiGuo Wu; K Ted Thurn; Benjamin Haley; Jimmy Clark; Taisa Priester; Gayle E Woloschak
Journal:  Anal Biochem       Date:  2008-08-26       Impact factor: 3.365

9.  Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing.

Authors:  Andrew M Siwkowski; Leila Malik; Christine C Esau; Martin A Maier; Edward V Wancewicz; Klaus Albertshofer; Brett P Monia; C Frank Bennett; Anne B Eldrup
Journal:  Nucleic Acids Res       Date:  2004-05-17       Impact factor: 16.971

10.  Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element.

Authors:  Sabyasachi Ganguly; Binay Chaubey; Snehlata Tripathi; Alok Upadhyay; Prasad V S V Neti; Roger W Howell; Virendra Nath Pandey
Journal:  Oligonucleotides       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.